Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Luqa Pharma Out-licenses AfMET Rights for AntiFungal; Keeps China Rights

publication date: Apr 18, 2012
Luqa Pharma, a drug company based in Hong Kong, out-licensed the rights for Ebernet®, a topical antifungal product, to NewBridge Pharmaceuticals for countries in Africa, the Middle East, Turkey and the Caspian Regions (AfMET). Luqa retains the rights to the drug in China and the greater Asia-Pacific region. Luqa acquired Asian and AfMET rights to Ebernet in a 2010 agreement with SALVAT Labs, the Spanish drug company that originally developed the product. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital